- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.07. | Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet | 3 | Zacks | ||
| 15.06. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.06. | Citizens upgrades Lyell Immunopharma stock price target on trial progress | 2 | Investing.com | ||
| 12.06. | Lyell Immunopharma, Inc: Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress | 1 | GlobeNewswire (USA) | ||
| 09.06. | H.C. Wainwright reiterates Lyell Immunopharma stock rating on safety data | 1 | Investing.com | ||
| 09.06. | Lyell Immunopharma: Citizens bestätigt Rating nach positiven Sicherheitsdaten | 1 | Investing.com Deutsch | ||
| 09.06. | Citizens upgrades Lyell Immunopharma stock rating on safety data | 1 | Investing.com | ||
| LYELL IMMUNOPHARMA Aktie jetzt für 0€ handeln | |||||
| 08.06. | Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update | 1 | Benzinga.com | ||
| 08.06. | Lyell Immunopharma: Aktie steigt nach Anpassung von Krebsstudie | 1 | Investing.com Deutsch | ||
| 08.06. | Lyell Immunopharma, Inc: Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion | 129 | GlobeNewswire (Europe) | Gastrointestinal prophylaxis reduced Grade = 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe maximum tolerated dose has not yet been determinedNo difference is observed... ► Artikel lesen | |
| 04.06. | Lyell Immunopharma, Inc: Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress | 1 | GlobeNewswire (USA) | ||
| 03.06. | H.C. Wainwright bestätigt Kaufempfehlung für Lyell Immunopharma | 1 | Investing.com Deutsch | ||
| 03.06. | H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy | 1 | Investing.com | ||
| 01.05. | Baird initiates Lyell Immunopharma stock with outperform rating | 1 | Investing.com | ||
| 01.05. | BofA reiterates Lyell Immunopharma stock Underperform on rival exit | 3 | Investing.com | ||
| 23.03. | H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy | 3 | Investing.com | ||
| 16.03. | Lyell Immunopharma: Citizens bestätigt "Market Outperform" nach Fortschritten in Studien | 1 | Investing.com Deutsch | ||
| 16.03. | Citizens reiterates Lyell Immunopharma stock rating on trial progress | 1 | Investing.com | ||
| 12.03. | Lyell Immunopharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.03. | Lyell Immunopharma, Inc. - 10-K, Annual Report | 1 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,018 | +119,51 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| AMGEN | 316,35 | -1,75 % | NICE aims to cut funding for Amgen lung cancer drug Lumykras | ||
| BIOGEN | 174,26 | -0,59 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 03.07.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,018 | -5,04 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| INFLARX | 1,837 | -2,60 % | ANALYSE: InflaRx NV: Könnte die Aktie jetzt komplett einbrechen? - Was Sie jetzt noch wissen müssen | ||
| INTELLIA THERAPEUTICS | 13,280 | -9,90 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| EDITAS MEDICINE | 2,910 | -9,06 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| IBIO | 1,397 | +3,33 % | iBio, Inc.: iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study | Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove... ► Artikel lesen | |
| IMMUNITYBIO | 7,660 | -0,65 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,685 | -0,52 % | Immatics: Mehr als nur SUPRAME: Der Kapitalmarkt bewertet Immatics derzeit vor allem über SUPRAME. CEO Dr. Harpreet Singh ist überzeugt, dass die eigentliche Plattformvalidierung längst begonnen hat | ||
| LAKEFRONT BIOTHERAPEUTICS | 26,560 | -0,97 % | Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer | ||
| MANNKIND | 3,617 | -2,38 % | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D | Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE... ► Artikel lesen | |
| IMMUNIC | 12,860 | -0,92 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in July | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in July
09.07.2026 / 12:30 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,850 | +2,67 % | IOVANCE BIOTHERAPEUTICS, INC. - 8-K, Current Report | ||
| MOLECULIN BIOTECH | 2,440 | +2,95 % | Moleculin Biotech, Inc.: Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment | Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive... ► Artikel lesen |
LYELL IMMUNOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,40 % bei einem Aktienkurs von 15,185 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYELL IMMUNOPHARMA INC finden Sie auf Wallstreet Online.